Adrenal Cancer
Symptoms, Doctors, Treatments, Advances & More

Learn About Adrenal Cancer

What is the definition of Adrenal Cancer?
Adrenal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the adrenal glands (small glands that sit above each kidney). In most cases, the underlying cause of the condition is unknown. However, certain genetic conditions such as multiple endocrine neoplasia type 2, Li-Fraumeni syndrome, Von Hippel-Lindau syndrome, neurofibromatosis type I, and Carney complex are associated with an increased risk of developing adrenal tumors and cancer.
What are the alternative names for Adrenal Cancer?
  • Adrenal cancer
What are the different types of Adrenal Cancer?

Common conditions include: Adrenal Gland Adenoma, Pheochromocytoma

Who are the top Adrenal Cancer Local Doctors?
Elite in Adrenal Cancer
Endocrinology | Internal Medicine
Elite in Adrenal Cancer
Endocrinology | Internal Medicine

Rogel Cancer Center

1500 E Medical Center Dr, Floor B1 Reception A, 
Ann Arbor, MI 
Languages Spoken:
English

Gary D. Hammer, M.D., Ph.D. is Professor in Departments of InternalMedicine (MEND), Cell & Developmental Biology, and Molecular &Integrative Physiology. He currently serves as Director of EndocrineOncology Program in Rogel Cancer Center where he holds the MillieSchembechler Professorship in Adrenal Cancer. He is past Director ofCenter for Organogenesis: Stem Cells & Regenerative Medicine. He hasbrokered the recent renaissance of the current Michigan team of adrenalscientists that includes a who’s who in the study of adrenal disease.He received the UofM Jerome Conn Award for Outstanding Research inInternal Medicine, the Endocrine Society Edwin B. Astwood Award forOutstanding Research and is a member of ASCI and AAP. He has served innumerous leadership roles at UofM and in the public and private sectorsincluding recent tenure on Board of Scientific Advisors for NCI. He isthe editor of four textbooks including Pathophysiology of Disease: AnIntroduction to Clinical Medicine (McGraw Hilll), and the upcomingAdrenal Section Editor for Degroot’s Endocrinology (Elsevier). He hasserved in numerous capacities for the world’s largest endocrineorganization, the Endocrine Society including his most recent role asPresident of the Society (2020-2021). An Advisor to the CongressionalH.E.L.P. committee - he co-authored the 21st Century Cancer ALERT(Access to Life-Saving Early detection, Research and Treatment) Act’’ lintroduced in Congress in 2009. He has been catalyst for the formationof two international cooperative groups, most recently the A5 (AmericanAustralian Asian Adrenal Alliance) that leverages collaboration tosecure projects from Pharma and funding agencies across the spectrum ofadrenal diseases. He is a cofounder of two companies - MILLENDO andSLING THERAPEUTICS that focus on rare endocrine diseases. Dr. Hammer is rated as an Elite provider by MediFind in the treatment of Adrenal Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Adrenal Cancer, Adrenocortical Carcinoma, Neuroblastoma, and Hereditary Neuroblastoma. Dr. Hammer is board certified in Endocrinology, Diabetes & Metabolism.

Elite in Adrenal Cancer
Endocrinology | Internal Medicine
Elite in Adrenal Cancer
Endocrinology | Internal Medicine

Rogel Cancer Center

1500 E Medical Center Dr, Floor B1 Reception A, 
Ann Arbor, MI 
Languages Spoken:
English
Offers Telehealth

Dr. Else’s primary appointment is with the Division of Metabolism, Endocrinology and Diabetes. He received his MD degree from the University of Hamburg, Germany. He pursued his clinical training at the University of Hamburg (Residency: Internal Medicine) and the University of Michigan (Residency: Internal Medicine, Fellowship: Endocrinology). His main research interests are the genetics of endocrine tumors. Dr. Else’s clinical practice focuses on the care for patients with benign and malignant endocrine tumors, particularly pheochromocytoma, adrenocortical tumors and neuroendocrine tumors as well as accompanying hormone excess syndromes (e.g Cushing syndrome, primary aldosteronism). Dr. Else has a particular interest in taking care of patients with hereditary syndromes that predispose to the development of endocrine tumors (e.g. Multiple Endocrine Neoplasia (MEN) type 1, MEN2A & MEN2B, Hereditary Paraganglioma Syndrome). He attends the Multidisciplinary Endocrine Oncology Clinic, where patients with tumors receive diagnostic procedures and treatment. In addition he is part of the Cancer Genetics Clinic, which evaluates patients for hereditary syndromes and also facilitates regular exams and surveillance for patients at risk for endocrine tumors. Dr. Else is rated as an Elite provider by MediFind in the treatment of Adrenal Cancer. He is also highly rated in 105 other conditions, according to our data. His clinical expertise encompasses Adrenal Cancer, Adrenocortical Carcinoma, Adrenal Gland Adenoma, Neuroendocrine Tumor, and Thyroidectomy. Dr. Else is board certified in Internal Medicine and Endocrinology, Diabetes & Metabolism.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Adrenal Cancer
Endocrinology
Elite in Adrenal Cancer
Endocrinology

University Of Colorado Hospital Authority

1635 Aurora Ct, 
Aurora, CO 
Languages Spoken:
English
Offers Telehealth

Margaret Wierman is an Endocrinologist practicing medicine in Aurora, Colorado. Dr. Wierman is rated as an Elite provider by MediFind in the treatment of Adrenal Cancer. She is also highly rated in 34 other conditions, according to our data. Her clinical expertise encompasses Adrenocortical Carcinoma, Pituitary Tumor, Adrenal Cancer, Hypothalamic Tumor, and Hormone Replacement Therapy (HRT).

What are the latest Adrenal Cancer Clinical Trials?
A Phase I Dose-escalation Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Background: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal glands. ACC often returns after tumors are removed with surgery. Less than 35% of people with ACC survive 5 years after diagnosis.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors

Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and ...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center